44 centralized collection varieties began to renew contracts with over one billion large varieties to choose between advance and retreat

Beginning on April 26, an inter-provincial alliance led by Henan, including 13 provinces and municipalities including Shanxi, Inner Mongolia, Hubei, Hunan, Guangxi, Hainan, Chongqing and Qinghai, plans to conduct 44 second, second, The four batches of medicines for which the agreement for the centralized purchase of medicines with quantity of medicines has expired were organized by the state to carry out centralized purchase of medicines with quantity of medicines
.
According to the "Purchasing Announcement of the Drug Alliance of the Thirteen Provinces (Districts, Cities, and Corps) of the New Corps of Henan, Jin, Mengqi, Hunan, Guiqiong, Yu, Guiqing, and Ning", the registration period for enterprises is up to May 6
.
According to the announcement, these 44 varieties mainly involve oral regular-release, sustained-release and controlled-release and injections, covering many common chronic diseases and diseases mainly based on drug treatment
.
The second and fourth batches of expired products from the 13-province alliance will be renewed and the competition will start
.
The "1+N" pattern increases the difficulty of selecting large varieties.
In the list of products renewed by the alliance of 13 provinces, autonomous regions and municipalities this time, parecoxib is one of the large varieties that the industry is more concerned about.
The non-steroidal anti-inflammatory drug with selective cyclooxygenase-2 inhibitor for injection has the characteristics of good analgesic effect, rapid onset of action and long-lasting effect compared with traditional preparations
.
At present, a "27+1" pattern has been formed, and the market competition will inevitably become more intense after the contract is renewed
.
From the perspective of terminal data, the market share of this large variety is being reshaped: the domestic market of parecoxib continues to expand, and the terminal sales of Chinese public medical institutions in 2020 will exceed 2 billion yuan, a year-on-year increase of 10.
22%
.
It is worth noting that in the results of the fourth batch of nationally selected drugs, the average price reduction of the drugs to be selected is 52%, and the highest price reduction is 96%, which is Qilu Pharmaceutical's Parecoxib Sodium for Injection (40mg/bottle), with a unit price of 3.
5 yuan.

.
The results of the centralized acquisition have already redistributed the market
.
The current situation is that the original manufacturer Pfizer's parecoxib injection plus 30 domestic pharmaceutical companies have been approved to produce parecoxib sodium for injection, of which 27 have been reviewed, including Kelun Pharmaceutical, Chia Tai Tian Qing, Hengrui, Buchang Pharmaceutical,
etc.
The data shows that the domestic sales of parecoxib injections have grown rapidly.
After breaking through the 1 billion yuan mark in 2018, they continued to climb, and the sales in 2020 will exceed 2 billion yuan.

.
The growth is very fast, but the regional alliance's centralized procurement and renewal, whether or not to need to make a choice with the enterprise
.
As far as the pattern is concerned, the top five market share of this variety in 2020 are: Pfizer 43.
18%, Kelun Pharmaceutical 26.
05%, Qilu Pharmaceutical 12.
09%, Chia Tai Tianqing 11.
06%, Jiangsu Osaikang Pharmaceutical 3.
98%, this group It can be seen from the data that there is an obvious trend of substitution in the original research drug market, and domestic varieties have seized more than half of the market share.
In the face of so many competitors, whether the bid can be renewed and the market outside the bid will face great pressure.
It is destined to not be a game.
A relaxing feast
.
In fact, facing the same choice is pantoprazole
.
Both pantoprazole sodium enteric-coated tablets and pantoprazole sodium for injection have entered the fourth batch of centralized procurement.
At the first stage of admission, Takeda's products were withdrawn
.
Proton pump inhibitors (PPIs) are the most widely used drugs for the treatment of peptic ulcers, with a large clinical demand, and their drug market accounts for nearly 40% of the peptic ulcer drug market
.
At present, omeprazole, rabeprazole, pantoprazole, lansoprazole and other products are mainly used in clinical practice
.
The problem is that pantoprazole and lansoprazole are first-generation proton pump inhibitors, with relatively low bioavailability and declining market share year by year
.
Still, the market is enticing
.
According to the data of Minet.
com, the total market sales of pantoprazole sodium for injection in domestic pharmaceutical medical and retail terminals in 2020 will be about 4.
343 billion yuan
.
Whether the contract renewal is successful depends on how the companies in the back row participate in the market competition.
Currently, there are as many as 156 approval numbers for pantoprazole sodium in China
.
In the list, there are many similar large varieties, and it has been less than a week for enterprises to choose to test their strategic decision-making ability
.
The contract renewal is imminent, Bayer, Luye, Hengrui have the opportunity.
The reporter noticed that a number of common chronic disease drugs were included in the list
.
Among them, acarbose is a commonly used hypoglycemic drug in clinical
.
According to data from Minet.
com, in recent years, China's online pharmacy terminal diabetes chemical drug market has expanded year by year, and it will be close to 1 billion yuan in 2021, a year-on-year increase of 95.
32%
.
And in 2021, the total market share of the TOP10 products of Chinese online pharmacy terminal diabetes drugs will exceed 70%, and the market share of the top three dapagliflozin tablets, metformin hydrochloride tablets, and acarbose tablets will all exceed 10%
.
In the previous second batch of national procurement, the bidding companies for acarbose included Sino-US Huadong, Luye Pharma and Bayer, a subsidiary of Huadong Medicine
.
Among them, Bayer won the right to choose acarbose (50mg) with a drop of 78% and a low price of 0.
18 yuan per tablet, which became the biggest explosion point of the second batch of national procurement
.
According to the data, 14 companies have passed the consistency evaluation of generic drugs, and there is 1 original drug company
.
It is conceivable that in the second and fourth batch of national procurement renewals, acarbose will still face fierce bidding
.
Clinically, the medicines for respiratory system diseases are mainly cough-relieving, expectorant-relieving and asthma-relieving drugs
.
According to data from Minet.
com, the sales of respiratory system chemicals in China's online pharmacies have grown rapidly in recent years, and will exceed the 1 billion yuan mark in 2021, a year-on-year increase of nearly 70%
.
Among the second and fourth batches of nationally adopted and renewed varieties, the commonly used clinical expectorant ambroxol is also on the list
.
In addition to the original pharmaceutical company Boehringer Ingelheim, there are currently many varieties of ambroxol hydrochloride in the market.
According to the data, in August 2018, Hengrui's ambroxol tablets were the first to be reviewed.
Shandong Yuxin, Changzhou four Consistency evaluation has been conducted on oral preparations of Pharma, Shanxi Qianyuan and Shanghai Xinyi Balance
.
As of September 2020, 232 production approvals for ambroxol have been approved in China
.
According to statistics, in the first quarter of 2020, domestic public hospitals in key provinces and cities accounted for 53% of domestic ambroxol, and 47.
08% of original research drugs
.
Among them, Changzhou Fourth Medicine and Chenxin Pharmaceutical have a relatively high proportion of domestic production.

.
According to the product renewal rhythm of the first and third batches of provinces/alliances, some experts predict that the volume of reports will be published next.
It is expected that the draft of the continuation rules and the official shortlisting rules will be released in May, and then the alliance will be re-bidding quotations, The results of the alliance's bid renewal will be announced, and the results of the bid renewal are expected to be executed in July
.
The second and fourth batches of nationally-organized centralized drug purchases have expired.
The selected batches are the name of the selected batch, the name of the dosage form, and the price specification of the dosage form.
1 The second batch of adefovir dipivoxil oral normal-release dosage form is 10 mg.
Oral normal release dosage form 50mg 3 Second batch of candesartan medoxomil oral normal release dosage form 4mg 4 Second batch of Sigiol oral normal release dosage form 20mg 5 Second batch of simvastatin oral normal release dosage form 20mg 6 Second batch of donepezil oral normal release dosage form Release dosage form 5mg 7 Second batch of trimetazidine sustained-release controlled release dosage form 35mg 8 Second batch of Ambrisentan oral normal release dosage form 5mg 9 Second batch of abiraterone